Cargando…

A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer

BACKGROUND: Previous studies have reported the effect of N(7)-methylguanosine (m(7)G) regulator methyltransferase like-1 protein (METTL1) in tumor initiation, metastasis, and chemosensitivity. However, the relationship between METTL1 and cancer immune infiltration is not validated and the prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Zijie, Xu, Jianye, Zhang, Zongpu, Fan, Yang, Xue, Hao, Guo, Xing, Deng, Lin, Wang, Shaobo, Zhao, Rongrong, Zhang, Ping, Li, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008260/
https://www.ncbi.nlm.nih.gov/pubmed/35432338
http://dx.doi.org/10.3389/fimmu.2022.795240
_version_ 1784687011359096832
author Gao, Zijie
Xu, Jianye
Zhang, Zongpu
Fan, Yang
Xue, Hao
Guo, Xing
Deng, Lin
Wang, Shaobo
Zhao, Rongrong
Zhang, Ping
Li, Gang
author_facet Gao, Zijie
Xu, Jianye
Zhang, Zongpu
Fan, Yang
Xue, Hao
Guo, Xing
Deng, Lin
Wang, Shaobo
Zhao, Rongrong
Zhang, Ping
Li, Gang
author_sort Gao, Zijie
collection PubMed
description BACKGROUND: Previous studies have reported the effect of N(7)-methylguanosine (m(7)G) regulator methyltransferase like-1 protein (METTL1) in tumor initiation, metastasis, and chemosensitivity. However, the relationship between METTL1 and cancer immune infiltration is not validated and the prognostic significance of METTL1 in pan-cancer remains unclear. METHODS: Clinical parameters, including gender, age, lifetime, stage, and treatment response were analyzed to evaluate the prognostic significance of METTL1. To evaluate protein level of METTL1, the METTL1 activity was generated by single sample gene set enrichment analysis. The one-class logistic regression algorithm was used to calculate the stemness indices based on transcriptomics and methylation data of pan-cancer and pluripotent stem cells. The relationship between METTL1 expression or activity and tumor immune infiltration were analyzed to explore the significance of METTL1 in tumor immunotherapy. Meanwhile, the correlation between three immunotherapeutic biomarkers and METTL1 was investigated. Finally, to calculate the association between drug sensitivity and METTL1 expression, spearman correlation analysis was performed. RESULTS: METTL1 was not intimately related to gender, age, tumor stage, or treatment outcome of the various cancers, but it displayed potential prognostic significance for evaluating patient survival. High METTL1 expression was related to tumor progression-relevant pathways. Moreover, METTL1 exhibited a distinct correlation with tumor immune microenvironment infiltration and stemness indices. In the anti-PD-L1 cohort, patients in treatment response group exhibited significantly higher METTL1 expression than those in the no/limited response group. Further analysis showed that tumor cell lines with higher METTL1 expression were more sensitive to drugs targeting chromatin histone methylation, ERK-MAPK and WNT signaling pathways. CONCLUSION: This study provides insight into the correlation of METTL1 with tumor immune infiltration and stemness in pan-cancer, revealing the significance of METTL1 for cancer progression and guiding more effective and generalized therapy strategies.
format Online
Article
Text
id pubmed-9008260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90082602022-04-15 A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer Gao, Zijie Xu, Jianye Zhang, Zongpu Fan, Yang Xue, Hao Guo, Xing Deng, Lin Wang, Shaobo Zhao, Rongrong Zhang, Ping Li, Gang Front Immunol Immunology BACKGROUND: Previous studies have reported the effect of N(7)-methylguanosine (m(7)G) regulator methyltransferase like-1 protein (METTL1) in tumor initiation, metastasis, and chemosensitivity. However, the relationship between METTL1 and cancer immune infiltration is not validated and the prognostic significance of METTL1 in pan-cancer remains unclear. METHODS: Clinical parameters, including gender, age, lifetime, stage, and treatment response were analyzed to evaluate the prognostic significance of METTL1. To evaluate protein level of METTL1, the METTL1 activity was generated by single sample gene set enrichment analysis. The one-class logistic regression algorithm was used to calculate the stemness indices based on transcriptomics and methylation data of pan-cancer and pluripotent stem cells. The relationship between METTL1 expression or activity and tumor immune infiltration were analyzed to explore the significance of METTL1 in tumor immunotherapy. Meanwhile, the correlation between three immunotherapeutic biomarkers and METTL1 was investigated. Finally, to calculate the association between drug sensitivity and METTL1 expression, spearman correlation analysis was performed. RESULTS: METTL1 was not intimately related to gender, age, tumor stage, or treatment outcome of the various cancers, but it displayed potential prognostic significance for evaluating patient survival. High METTL1 expression was related to tumor progression-relevant pathways. Moreover, METTL1 exhibited a distinct correlation with tumor immune microenvironment infiltration and stemness indices. In the anti-PD-L1 cohort, patients in treatment response group exhibited significantly higher METTL1 expression than those in the no/limited response group. Further analysis showed that tumor cell lines with higher METTL1 expression were more sensitive to drugs targeting chromatin histone methylation, ERK-MAPK and WNT signaling pathways. CONCLUSION: This study provides insight into the correlation of METTL1 with tumor immune infiltration and stemness in pan-cancer, revealing the significance of METTL1 for cancer progression and guiding more effective and generalized therapy strategies. Frontiers Media S.A. 2022-03-31 /pmc/articles/PMC9008260/ /pubmed/35432338 http://dx.doi.org/10.3389/fimmu.2022.795240 Text en Copyright © 2022 Gao, Xu, Zhang, Fan, Xue, Guo, Deng, Wang, Zhao, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gao, Zijie
Xu, Jianye
Zhang, Zongpu
Fan, Yang
Xue, Hao
Guo, Xing
Deng, Lin
Wang, Shaobo
Zhao, Rongrong
Zhang, Ping
Li, Gang
A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
title A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
title_full A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
title_fullStr A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
title_full_unstemmed A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
title_short A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
title_sort comprehensive analysis of mettl1 to immunity and stemness in pan-cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008260/
https://www.ncbi.nlm.nih.gov/pubmed/35432338
http://dx.doi.org/10.3389/fimmu.2022.795240
work_keys_str_mv AT gaozijie acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT xujianye acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT zhangzongpu acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT fanyang acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT xuehao acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT guoxing acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT denglin acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT wangshaobo acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT zhaorongrong acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT zhangping acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT ligang acomprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT gaozijie comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT xujianye comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT zhangzongpu comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT fanyang comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT xuehao comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT guoxing comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT denglin comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT wangshaobo comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT zhaorongrong comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT zhangping comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer
AT ligang comprehensiveanalysisofmettl1toimmunityandstemnessinpancancer